{
  "Clinical Information": [],
  "Patent Information": [],
  "Sequence Information": {
    "ID": "AP04606",
    "Peptide Name": "Arenicin-3 analog N6 (Synthetic AMPs, UCSS1a, 1S=S; BBL; Derivative: N6NH2)",
    "Source": "amino acid substitution, animal-derived, natural derivative",
    "Family": "Not found",
    "Gene": "Not found",
    "Sequence": "GFAWNVCVYRNGVRVCHRRAN",
    "Sequence Length": 21,
    "UniProt Entry": "",
    "Protein Existence": "Not found",
    "Biological Activity": [
      "Anti-Gram+",
      "Gram-",
      "Antifungal",
      "candidacidal",
      "Anti-inflammatory",
      "anti-sepsis"
    ],
    "Target Organism": "Not found",
    "Hemolytic Activity": "Not found",
    "Cytotoxicity": "Not found",
    "Binding Target": "Not found",
    "Linear/Cyclic": "Not found",
    "N-terminal Modification": "Not found",
    "C-terminal Modification": "Not found",
    "Nonterminal Modifications and Unusual Amino Acids": "Not found",
    "Stereochemistry": "Not found",
    "Structure": "Beta",
    "Structure Description": "Not found",
    "Helical Wheel Diagram": "Not found",
    "PDB ID": "5Y0H",
    "Predicted Structure": "Not found",
    "Formula": "Not found",
    "Absent Amino Acids": "Not found",
    "Common Amino Acids": "Not found",
    "Mass": "Not found",
    "PI": "Not found",
    "Basic Residues": "Not found",
    "Acidic Residues": "Not found",
    "Hydrophobic Residues": "Not found",
    "Net charge": 5,
    "Boman Index": 2.61,
    "Hydrophobicity": "Not found",
    "Aliphatic Index": "Not found",
    "Half Life": "Not found",
    "Extinction Coefficient Cystines": "Not found",
    "Absorbance 280nm": "Not found",
    "Polar Residues": "Not found",
    "Function": "Not found",
    "Hydrophobic residue%": "48%",
    "Crucial residues": ""
  },
  "Literature Information": {
    "Literature": "Sequence analysis: APD analysis reveals that this sequence is similar (76.19%) toArenicin-3V=R: 19%, N: 14%, C=A: 10%.Chemical modification: one disulfide bond: C7-C16.Activity: active against Gram- bacteria E. coli CVCC195 or CVCC1515 or CICC21530 serotype O157:H7 (MIC 0.5-1.0 ug/ml), S. typhimurium ATCC14028 (MIC 2 ug/ml), S. enteritidis CVCC3377 (MIC 0.25 ug/ml), S. pullorum CVCC1789 or CVCC1802 (MIC 0.5 ug/ml), S. choleraesuis CVCC503 (MIC 2 ug/ml), P. aeruginosa CICC10419 or CICC21630 (MIC 4-8 ug/ml), Gram+ S. aureus ATCC43300 MRSA or ATCC25923 (MIC 0.25-16 ug/ml), S. suis CVCC606 (MIC 16 ug/ml), E. faecium CMCC1.2136 (MIC 4 ug/ml), B. subtilis ATCC6633 (MIC 0.5 ug/ml), fungi C. albicans CGMCC2.2411 (MIC 64 ug/ml).MOA:bacteria:E. coli: it permeated bacterial membranes.Structure:  NMR structure.You can rotate, zoom, and view the 3D structureherein the PDB.In vitro toxicity: murine RBC: 2% hemolysis at 256 ug/ml (low hemo.lytic). Less toxic to RAW264.7 cells than Arenicin-3 analog N1.Animal model:mouse: IP infection, peptide treatment (IP) showed protective effects in S. enteritidis-induced peritonitis (5 mg/kg, 66.7% survival), E. coli-induced peritonitis (2.5 mg/kg, 100% survival), and LPS-induced endotoxemia (2.5 mg/kg: 33.3% survical).Anti-inflammatory: it suppressed the release of TNF-alpha, IL-6, and IL-1beta in LPS-induced inflammation in mice.Resistance development:yes:bacteria:E. coli: E. coli developed resistance to N6NH2 (C-terminally amidated form) in a multiple passage experiment (Wang et al., 2022).",
    "Author": "Yang N, Liu X, Teng D, Li Z, Wang X, Mao R, Wang X, Hao Y, Wang J. 2017",
    "Reference": "Sci Rep. 2017 Jun 13;7(1):3392. doi: 10.1038/s41598-017-03664-2.PubMed",
    "Title": "Antibacterial and detoxifying activity of NZ17074 analogues with multi-layers of selective antimicrobial actions against Escherichia coli and Salmonella enteritidis."
  },
  "3D Structure": []
}